Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication.

Nahon P, Ganne-Carrié N.

JHEP Rep. 2019 Nov 18;1(6):480-489. doi: 10.1016/j.jhepr.2019.11.001. eCollection 2019 Dec. Review.

2.

Epidemiology and surveillance for hepatocellular carcinoma: New trends.

Singal AG, Lampertico P, Nahon P.

J Hepatol. 2020 Feb;72(2):250-261. doi: 10.1016/j.jhep.2019.08.025. Review.

PMID:
31954490
3.

Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis.

Zarski JP, David-Tchouda S, Trocme C, Margier J, Vilotitch A, Hilleret MN, Cagnot C, Boursier V, Ziol M, Sutton A, Layese R, Audureau E, Roudot-Thoraval F, Nahon P.

Clin Res Hepatol Gastroenterol. 2019 Dec 12. pii: S2210-7401(19)30256-6. doi: 10.1016/j.clinre.2019.11.005. [Epub ahead of print]

PMID:
31839535
4.

TIPS for management of portal-hypertension-related complications in patients with cirrhosis.

Allaire M, Walter A, Sutter O, Nahon P, Ganne-Carrié N, Amathieu R, Nault JC.

Clin Res Hepatol Gastroenterol. 2019 Oct 26. pii: S2210-7401(19)30217-7. doi: 10.1016/j.clinre.2019.09.003. [Epub ahead of print]

PMID:
31662286
5.

Comparing interferon-free with interferon-based regimens in HCV patients: Rogers phenomenon and Simpson's paradox.

Carrat F, Nahon P, Fontaine H, Pol S, Hejblum G.

J Viral Hepat. 2019 Oct 26. doi: 10.1111/jvh.13225. [Epub ahead of print]

PMID:
31654535
6.

Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma.

Rochigneux P, Nault JC, Mallet F, Chretien AS, Barget N, Garcia AJ, Del Pozo L, Bourcier V, Blaise L, Grando-Lemaire V, N'Kontchou G, Nahon P, Seror O, Ziol M, Ganne-Carrié N, Olive D.

Oncoimmunology. 2019 May 25;8(8):1615818. doi: 10.1080/2162402X.2019.1615818. eCollection 2019.

7.

Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis.

Rekik S, Allaire M, Mumana A, Guyot E, Nkontchou G, Grando V, Blaise L, Ziol M, Nahon P, Ganne-Carrié N, Sutter O, Seror O, Nault JC.

J Gastroenterol Hepatol. 2020 Jan;35(1):142-150. doi: 10.1111/jgh.14763. Epub 2019 Jul 31.

PMID:
31237018
8.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.

Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman-Rossi J.

Hepatology. 2020 Jan;71(1):164-182. doi: 10.1002/hep.30811. Epub 2019 Aug 12.

PMID:
31206197
9.

Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results.

N'Kontchou G, Nault JC, Sutter O, Bourcier V, Coderc E, Grando V, Nahon P, Ganne-Carrié N, Diallo A, Sellier N, Seror O.

Liver Cancer. 2019 May;8(3):172-185. doi: 10.1159/000489319. Epub 2018 Jun 28.

10.

Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence?

Nault JC, Nahon P.

Gastroenterology. 2019 May;156(6):1558-1560. doi: 10.1053/j.gastro.2019.03.027. Epub 2019 Mar 26. No abstract available.

PMID:
30926345
11.

A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Bayard Q, Gustot T, Deviere J, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J, Nault JC.

Hepatology. 2019 Jul;70(1):231-240. doi: 10.1002/hep.30623. Epub 2019 Apr 25.

PMID:
30908678
12.

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.

Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group.

Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13.

PMID:
30768988
13.

Hepatocellular carcinoma in the setting of alcohol-related liver disease.

Ganne-Carrié N, Nahon P.

J Hepatol. 2019 Feb;70(2):284-293. doi: 10.1016/j.jhep.2018.10.008. Review.

PMID:
30658729
14.

Fa(s)t assessment of the liver graft: Is it relevant?

Nahon P, Soubrane O.

J Hepatol. 2019 Mar;70(3):346-347. doi: 10.1016/j.jhep.2018.12.017. Epub 2019 Jan 3. No abstract available.

PMID:
30612827
15.

Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.

Salmon-Ceron D, Nahon P, Layese R, Bourcier V, Sogni P, Bani-Sadr F, Audureau E, Merchadou L, Dabis F, Wittkop L, Roudot-Thoraval F; ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups.

Hepatology. 2019 Sep;70(3):939-954. doi: 10.1002/hep.30400. Epub 2019 Mar 15.

PMID:
30569448
16.

Elevated adiponectin and sTNFRII serum levels can predict progression to hepatocellular carcinoma in patients with compensated HCV1 cirrhosis.

Bastard JP, Fellahi S, Audureau É, Layese R, Roudot-Thoraval F, Cagnot C, Mahuas-Bourcier V, Sutton A, Ziol M, Capeau J, Nahon P; ANRS CO12 CirVir group.

Eur Cytokine Netw. 2018 Sep 1;29(3):112-120. doi: 10.1684/ecn.2018.0413.

PMID:
30547888
17.

Reply.

Costentin CE, Layese R, Roudot-Thoraval F, Audureau E, Nahon P; ANRS C012 CirVir group.

Gastroenterology. 2019 Jan;156(1):289-290. doi: 10.1053/j.gastro.2018.11.046. Epub 2018 Nov 23. No abstract available.

PMID:
30472229
18.

Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.

Brichler S, Nahon P, Zoulim F, Layese R, Bourcier V, Audureau E, Sutton A, Letouze E, Cagnot C, Marcellin P, Guyader D, Roulot D, Pol S, de Ledinghen V, Zarski JP, Calès P, Tran A, Peron JM, Mallat A, Riachi G, Grange JD, Blanc JF, Bacq Y, Ouzan D, Bronowicki JP, Mathurin P, Larrey D, Alric L, Attali P, Serfaty L, Pilette C, Bourlière M, Thabut D, Silvain C, Wartelle C, Zucman D, Christidis C, Roudot-Thoraval F, Ganne-Carrie N; ANRS CO12 CirVir study group.

J Viral Hepat. 2019 Mar;26(3):384-396. doi: 10.1111/jvh.13029. Epub 2019 Jan 16.

PMID:
30380181
19.

PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.

Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, Imbeaud S, Gustot T, Deviere J, Debette S, Amouyel P, Bioulac-Sage P, Calderaro J, Ganne-Carrié N, Laurent A, Blanc JF, Guyot E, Sutton A, Ziol M, Zucman-Rossi J, Nault JC.

Int J Cancer. 2019 Feb 1;144(3):533-544. doi: 10.1002/ijc.31910. Epub 2018 Nov 9.

20.

Percutaneous ablation for HCC eligible to transplantation: providing more opportunities of remission in the context of graft shortage.

Nault JC, Nahon P, Séror O.

Hepatobiliary Surg Nutr. 2018 Aug;7(4):302-304. doi: 10.21037/hbsn.2018.06.01. No abstract available.

21.

Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.

Moreau R, Elkrief L, Bureau C, Perarnau JM, Thévenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-Hourmand I, Robic MA, d'Alteroche L, Di Martino V, Ripault MP, Pauwels A, Grangé JD, Carbonell N, Bronowicki JP, Payancé A, Rautou PE, Valla D, Gault N, Lebrec D; NORFLOCIR Trial Investigators.

Gastroenterology. 2018 Dec;155(6):1816-1827.e9. doi: 10.1053/j.gastro.2018.08.026. Epub 2018 Aug 23.

22.

Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis.

Allaire M, Rekik S, Layese R, Mumana A, Guyot E, Nkontchou G, Bourcier V, Grando V, Ziol M, Nahon P, Ganne-Carrié N, Sutter O, Audureau E, Seror O, Nault JC.

Dig Liver Dis. 2019 Jan;51(1):86-94. doi: 10.1016/j.dld.2018.07.014. Epub 2018 Jul 24.

PMID:
30126822
23.

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19.

PMID:
30031138
24.

Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis.

Nguyen-Khac E, Thiele M, Voican C, Nahon P, Moreno C, Boursier J, Mueller S, de Ledinghen V, Stärkel P, Gyune Kim S, Fernandez M, Madsen B, Naveau S, Krag A, Perlemuter G, Ziol M, Chatelain D, Diouf M.

Lancet Gastroenterol Hepatol. 2018 Sep;3(9):614-625. doi: 10.1016/S2468-1253(18)30124-9. Epub 2018 Jul 6.

PMID:
29983372
25.

Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort.

Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Beso Delgado M, Teicher E, Layese R, Roudot-Thoraval F, Fontaine H, Sobesky R, Salmon-Céron D, Samuel D, Seror O, Nahon P, Meyer L, Duclos-Vallée JC; ANRS HC EP 25 Prethevic, ANRS CO13 HepaVih and ANRS CO12 CirVir Study Groups.

Liver Int. 2019 Jan;39(1):136-146. doi: 10.1111/liv.13921. Epub 2018 Jul 30.

26.

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.

Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir Group.

Gastroenterology. 2018 Aug;155(2):431-442.e10. doi: 10.1053/j.gastro.2018.04.027. Epub 2018 May 3.

PMID:
29729258
27.

Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.

Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, DI Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1245-1259. doi: 10.1002/hep.30034. Epub 2018 Jul 10.

PMID:
29663511
28.

Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.

Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Zucman D, Di Martino V, Bagnis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir group.

Am Heart J. 2018 Apr;198:4-17. doi: 10.1016/j.ahj.2017.10.024. Epub 2017 Nov 7.

PMID:
29653647
29.

Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort).

Wendum D, Layese R, Ganne-Carrié N, Bourcier V, Merabtene F, Cagnot C, Sauce E, Barget N, Bedossa P, Terris B, Selves J, Bioulac-Sage P, Sturm N, Sattonnet C, Nahon P, Roudot-Thoraval F, Ziol M; ANRS CO12 CirVir Group.

Hepatology. 2018 Oct;68(4):1534-1548. doi: 10.1002/hep.29927.

30.

Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.

Chalaye J, Costentin CE, Luciani A, Amaddeo G, Ganne-Carrié N, Baranes L, Allaire M, Calderaro J, Azoulay D, Nahon P, Seror O, Mallat A, Soussan M, Duvoux C, Itti E, Nault JC.

J Hepatol. 2018 Aug;69(2):336-344. doi: 10.1016/j.jhep.2018.02.018. Epub 2018 Mar 6.

PMID:
29518452
31.

Determination of candidate metabolite biomarkers associated with recurrence of HCV-related hepatocellular carcinoma.

Liu Z, Nahon P, Li Z, Yin P, Li Y, Amathieu R, Ganne-Carrié N, Ziol M, Sellier N, Seror O, Le Moyec L, Savarin P, Xu G.

Oncotarget. 2017 Dec 15;9(5):6245-6258. doi: 10.18632/oncotarget.23500. eCollection 2018 Jan 19.

32.

Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake.

Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, Vilgrain V.

Br J Radiol. 2018 Oct;91(1090):20170436. doi: 10.1259/bjr.20170436. Epub 2018 Feb 27. Review.

33.

Eating Patterns in Patients with Compensated Cirrhosis: A Case-Control Study.

Buscail C, Bourcier V, Fezeu LK, Roulot D, Brulé S, Ben-Abdesselam Z, Cagnot C, Hercberg S, Nahon P, Ganne-Carrié N, Julia C.

Nutrients. 2018 Jan 10;10(1). pii: E60. doi: 10.3390/nu10010060.

34.

Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis.

Whitfield JB, Masson S, Liangpunsakul S, Hyman J, Mueller S, Aithal G, Eyer F, Gleeson D, Thompson A, Stickel F, Soyka M, Daly AK, Cordell HJ, Liang T, Foroud T, Lumeng L, Pirmohamed M, Nalpas B, Bence C, Jacquet JM, Louvet A, Moirand R, Nahon P, Naveau S, Perney P, Podevin P, Haber PS, Seitz HK, Day CP, Mathurin P, Morgan TM, Seth D; GenomALC Consortium.

Alcohol. 2018 Feb;66:1-7. doi: 10.1016/j.alcohol.2017.07.006. Epub 2017 Sep 23.

35.

Is "Segmentectomy" a Suitable Term to Use in Patients Undergoing Hepatic Segmental 90Y Radioembolization for the Treatment of Hepatocellular Carcinoma Up to 3 cm?

Seror O, Nault JC, N'Kontchou G, Sutter O, Nahon P.

Radiology. 2017 Nov;285(2):690-691. doi: 10.1148/radiol.2017170852. No abstract available.

PMID:
29045224
36.

Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.

Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O.

J Hepatol. 2018 Apr;68(4):783-797. doi: 10.1016/j.jhep.2017.10.004. Epub 2017 Oct 13. Review.

PMID:
29031662
37.

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences.

Pol S, Haour G, Fontaine H, Dorival C, Petrov-Sanchez V, Bourliere M, Capeau J, Carrieri P, Larrey D, Larsen C, Marcellin P, Pawlostky JM, Nahon P, Zoulim F, Cacoub P, de Ledinghen V, Mathurin P, Negro F, Pageaux GP, Yazdanpanah Y, Wittkop L, Zarski JP, Carrat F; French Anrs Co22 Hepather Cohort.

Aliment Pharmacol Ther. 2017 Dec;46(11-12):1054-1060. doi: 10.1111/apt.14352. Epub 2017 Oct 9.

38.

Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.

Thabut D, Pauwels A, Carbonell N, Remy AJ, Nahon P, Causse X, Cervoni JP, Cadranel JF, Archambeaud I, Bramli S, Ehrhard F, Ah-Soune P, Rostain F, Pariente A, Vergniol J, Dupuychaffray JP, Pelletier AL, Skinazi F, Guillygomarc'h A, Vitte RL, Henrion J, Combet S, Rudler M, Bureau C; des Hépato-Gastroentérologues des Hôpitaux Généraux (ANGH); Club Francophone pour l'Etude de l'Hypertension Portale (CFETHTP); CHOC Study Group collaborators:.

J Hepatol. 2017 Dec 14;68(1):73-81. doi: 10.1016/j.jhep.2017.09.002. Epub 2017 Sep 13.

PMID:
28918131
39.

Management and surveillance of compensated cirrhosis

Nahon P, Fanica D.

Rev Prat. 2017 Sep;67(7):730-735. French.

PMID:
30512766
40.

Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.

Sutter O, Calvo J, N'Kontchou G, Nault JC, Ourabia R, Nahon P, Ganne-Carrié N, Bourcier V, Zentar N, Bouhafs F, Sellier N, Diallo A, Seror O.

Radiology. 2017 Sep;284(3):877-886. doi: 10.1148/radiol.2017161413. Epub 2017 Apr 28.

PMID:
28453431
41.

Nuclear magnetic resonance metabolomics and human liver diseases: The principles and evidence associated with protein and carbohydrate metabolism.

Le Moyec L, Triba MN, Nahon P, Bouchemal N, Hantz E, Goossens C, Amathieu R, Savarin P.

Biomed Rep. 2017 Apr;6(4):387-395. doi: 10.3892/br.2017.868. Epub 2017 Mar 3.

42.

Reply.

Durand-Zaleski I, Bulsei J, Seror O, Nahon P.

Hepatology. 2017 Jul;66(1):300-301. doi: 10.1002/hep.29193. Epub 2017 May 26. No abstract available.

PMID:
28380685
43.

Reply.

Nahon P, Seror O, Durand-Zaleski I.

Hepatology. 2017 Jul;66(1):298-299. doi: 10.1002/hep.29174. Epub 2017 May 26. No abstract available.

PMID:
28318039
44.

Constitutional and functional genetics of human alcohol-related hepatocellular carcinoma.

Nahon P, Nault JC.

Liver Int. 2017 Nov;37(11):1591-1601. doi: 10.1111/liv.13419. Epub 2017 Apr 11. Review.

PMID:
28296015
45.

Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States.

Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, Layese R, Costentin C, Cagnot C, Durand-Zaleski I, Chevreul K; ANRS CO12 CirVir and CHANGH groups.

Hepatology. 2017 Apr;65(4):1237-1248. doi: 10.1002/hep.28961. Epub 2017 Feb 8.

PMID:
28176349
46.

Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.

Mueller S, Nahon P, Rausch V, Peccerella T, Silva I, Yagmur E, Straub BK, Lackner C, Seitz HK, Rufat P, Sutton A, Bantel H, Longerich T.

Hepatology. 2017 Jul;66(1):96-107. doi: 10.1002/hep.29099. Epub 2017 May 9.

PMID:
28170108
47.

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.

Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Leroy V, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Dharancy S, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-Thoraval F; ANRS CO12 CirVir Group.

Gastroenterology. 2017 Jan;152(1):142-156.e2. doi: 10.1053/j.gastro.2016.09.009. Epub 2016 Sep 15. Erratum in: Gastroenterology. 2019 Feb 25;:.

PMID:
27641509
48.

Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results.

Seror O, N'Kontchou G, Nault JC, Rabahi Y, Nahon P, Ganne-Carrié N, Grando V, Zentar N, Beaugrand M, Trinchet JC, Diallo A, Sellier N.

Radiology. 2016 Sep;280(3):981. doi: 10.1148/radiol.2016164017. No abstract available.

PMID:
27533029
49.

Reply to "A strong message is needed to address the issue of HCC recurrence after DAA therapy".

Carrat F, Nahon P, Duclos-Vallée JC, Pageaux GP, Fontaine H, Pol S; ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts).

J Hepatol. 2016 Dec;65(6):1269-1270. doi: 10.1016/j.jhep.2016.07.030. Epub 2016 Jul 29. No abstract available.

PMID:
27480588
50.

The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization.

Rekik S, Guyot E, Bhais M, Ajavon Y, Grando V, Bourcier V, Nkontchou G, Nahon P, Sellier N, Seror O, Ganne-Carrie N, Nault JC.

Dig Liver Dis. 2016 Sep;48(9):1088-92. doi: 10.1016/j.dld.2016.06.005. Epub 2016 Jun 15.

PMID:
27375209

Supplemental Content

Support Center